National Institute on Drug Abuse; Notice of Meeting, 73604 [2023-23628]
Download as PDF
<![CDATA[
73604
Federal Register / Vol. 88, No. 206 / Thursday, October 26, 2023 / Notices
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3F58, Rockville, MD
20852, 240–669–5199, cerritem@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 20, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–23626 Filed 10–25–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual
meeting and is open to the public, as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance such as sign language
interpretation or other reasonable
accommodations to view the meeting,
should notify Dr. Jeanette Marketon via
email at jeanette.marketon@nih.gov five
days in advance of the meeting. The
open session will be videocast and can
be accessed from the NIH Videocasting
and Podcasting website (https://
videocast.nih.gov/).
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The intramural programs
and projects as well as the grant
applications and/or contract proposals
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with intramural
programs and projects as well as the
grant applications and/or contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: February 6, 2024.
Closed: 10:30 a.m. to 11:45 a.m. Agenda:
To review and evaluate grant applications.
VerDate Sep<11>2014
17:23 Oct 25, 2023
Jkt 262001
Closed: 11:45 a.m. to 12:15 p.m. Agenda:
Report to Council from the NIDA Board of
Scientific Counselors (BSC).
Open: 12:45 p.m. to 5:00 p.m. Agenda:
Presentations and other business of the
Council.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North,
RM 09D08, 11601 Landsdown Street,
Bethesda, MD 20852 301–443–6480 sweiss@
nida.nih.gov.
Contact Person: Jeanette Marketon, Ph.D.,
Director, Office of Extramural Policy,
Division of Extramural Research Office of
Extramural Policy, National Institute on Drug
Abuse, NIH, Three White Flint North, RM
09C68, 11601 Landsdown Street, Bethesda,
MD 20852, 301–443–5239
jeanette.marketon@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to Dr. Jeanette Marketon at
jeanette.marketon@nih.gov. The statement
should include the name, address, telephone
number and when applicable, the business or
professional affiliation of the interested
person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: October 20, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–23628 Filed 10–25–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: November 20, 2023.
Time: 9:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 903 South 4th Street, Room RML 31/
3118, Hamilton, MT 59840 (Virtual Meeting).
Contact Person: Kristin L. McNally, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 903
South 4th Street, Room RML 31/3118,
Hamilton, MT 59840, mcnallyk@
niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 20, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–23627 Filed 10–25–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA—2023–0029; OMB No.
1660–0016]
Agency Information Collection
Activities: Proposed Collection,
Comment Request; Revision to
National Flood Insurance Program
Maps: Application Forms and
Instructions for LOMRs and CLOMRs
Federal Emergency
Management Agency, Department of
Homeland Security.
ACTION: 60-Day notice of renewal and
request for comments.
AGENCY:
The Federal Emergency
Management Agency (FEMA), as part of
its continuing effort to reduce
paperwork and respondent burden,
invites the general public to take this
opportunity to comment on a renewal of
SUMMARY:
E:\FR\FM\26OCN1.SGM
26OCN1
]]>Agencies
[Federal Register Volume 88, Number 206 (Thursday, October 26, 2023)]
[Notices]
[Page 73604]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-23628]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual meeting and is open to the
public, as indicated below. Individuals who plan to view the virtual
meeting and need special assistance such as sign language
interpretation or other reasonable accommodations to view the meeting,
should notify Dr. Jeanette Marketon via email at
[email protected] five days in advance of the meeting. The open
session will be videocast and can be accessed from the NIH Videocasting
and Podcasting website (https://videocast.nih.gov/).
A portion of the meeting will be closed to the public in accordance
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6),
Title 5 U.S.C., as amended. The intramural programs and projects as
well as the grant applications and/or contract proposals and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with intramural programs and projects
as well as the grant applications and/or contract proposals, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: February 6, 2024.
Closed: 10:30 a.m. to 11:45 a.m. Agenda: To review and evaluate
grant applications.
Closed: 11:45 a.m. to 12:15 p.m. Agenda: Report to Council from
the NIDA Board of Scientific Counselors (BSC).
Open: 12:45 p.m. to 5:00 p.m. Agenda: Presentations and other
business of the Council.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown
Street, Bethesda, MD 20852 301-443-6480 [email protected].
Contact Person: Jeanette Marketon, Ph.D., Director, Office of
Extramural Policy, Division of Extramural Research Office of
Extramural Policy, National Institute on Drug Abuse, NIH, Three
White Flint North, RM 09C68, 11601 Landsdown Street, Bethesda, MD
20852, 301-443-5239 [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to Dr. Jeanette Marketon at
[email protected]. The statement should include the name,
address, telephone number and when applicable, the business or
professional affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: October 20, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2023-23628 Filed 10-25-23; 8:45 am]
BILLING CODE 4140-01-P
